Boker A, Kimball AB, Rolz-Cruz G. Biologicals in the treatment of psoriasis.. Current opinion in investigational drugs (London, England : 2000). 2007;8(11):939-46.
See also:
Psoriasis Publications
Abstract
Psoriasis is a chronic inflammatory skin disorder that can cause substantial disability. The recognition of psoriasis as an immunologically mediated disease led to the development of agents that specifically target key steps in the pathological process. This review focuses on these biological agents, and presents results from phase II and III clinical trials together with the safety profile and approved indications for alefacept, efalizumab, etanercept, infliximab and adalimumab. Preliminary safety and efficacy data for the newer therapeutic agents, such as CNTO-1275 and ABT-874, are also described.